Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease

Europace

Volumn 12, Issue 12, 2010, Pages 1713-1718

  Luan, Ying ^a   Guo, Yuanyuan ^a   Li, Shufeng ^a   Yu, Bo ^a   Zhu, Sui ^a   Li, Shaojun ^a   Li, Ning ^a   Tian, Zhen ^a   Peng, Chenghai ^a   Cheng, Jiali ^a   Li, Qingsong ^a   Cui, Jinjin ^a   Tian, Ye ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Hs C reactive protein; IL 18; Inflammation; MMP 9

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 18; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT ATRIUM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM;

ADULT; AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HEART DISEASES; HUMANS; INTERLEUKIN-18; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649352200     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq321     Document Type: Article

References (33)

1. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4.
2. Gaudino M, Andreotti F, Zamparelli R, DiCastelnuovo A, Nasso G, Burzotta F et al. The-174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003;108:II195-9.
3. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
4. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence ofatrialfibrillation. Circulation 2001;104:2886-91.
5. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73: 213-24.
6. Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 2005;152:863-8.
7. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997;275:206-9.
8. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A et al. Evi-dence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEBJ 2004;18:1752-4.
9. Everett BM, Bansal S, Rifai N, Buring JE, Ridker PM. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 2009; 202:282-8.
10. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-50.
11. Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur J Immunol 2000;30:3057-60.
12. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol 2007;292:H1561-7.
13. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008;155:303-9.
14. Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A et al. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett 2004;569:156-60.
15. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrilla-tion. J Am Coll Cardiol 2004;43:818-25.
16. Katritsis DG, Panagiotakos DB, Karvouni E, Giazitzoglou E, Korovesis S, Paxinos G et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003;92:1116-9.
17. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ et al. Pathophy-siology and prevention of atrial fibrillation. Circulation 2001;103:769-77.
18. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence ofatrialfibrillation. Heart 2008;94:200-4.
19. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92.
20. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduc-tion and atrial fibrillation. Circulation 2005;111:2881-8.
21. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
22. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and elec-trical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003;9:RA225-9.
23. Nattel S. New ideas about atrialfibrillation 50 years on. Nature 2002;415:219-26.
24. Ellinor PT, Low A, Patton KK, Shea MA, Mac Rae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol 2006;97:1346-50.
25. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009;6: 192-9.
26. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135:361-9.
27. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642-8.
28. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57.
29. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005;95: 764-7.
30. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25: 1100-7.
31. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007;101:839-47.
32. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004;109: 363-8.
33. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86:1259-65.